IDC2024 | Congen Pharma shares "EMPHASES Peptide Synthesis Technology and its Application in Pharmaceutical Peptide Synthesis"

Publish Time:

2024-07-31


The "IDC2024 Peptide and Peptide Conjugate Drug R&D Quality Control Forum," hosted by Shanghai Aoshun Business Consulting and Yaojingtong Bio, was held in Suzhou on July 25-26. Themed "Focusing on Industry Hotspots, Heading for the Blue Sea of Pharmaceuticals," the conference brought together experts, scholars, and attendees from across the country to exchange and share insights on the innovative R&D of peptide drugs and peptide conjugate drugs, drug quality control and process development, and CMC discussions.

Zheng Qingquan, founder and chairman of Congen Pharma, was invited to attend and gave a presentation titled "EMPHASES ® Peptide Synthesis Technology and Its Application in the Synthesis of Pharmaceutical Peptides."

In his presentation, Mr. Zheng Qingquan elaborated on the characteristics of Congen Pharma's pioneering EMPHASES ® peptide synthesis technology. This technology, with its green, efficient, scalable production capabilities, and significant cost-effectiveness, provides strong technical support for the synthesis of pharmaceutical peptides. Through a series of detailed data, he showcased the application results of EMPHASES ® in the synthesis of tirzepatide: not only significantly improving the purity of peptide fragments, but also greatly shortening the synthesis cycle, effectively optimizing yield, and reducing the generation of by-products, fully demonstrating the advantages of this technology. 
 

 

 

About Congen Pharma

 

Congen Pharma focuses on the R&D and production of pharmaceutical peptides and cosmetic peptides. It has established a green and efficient EMPHASES ® peptide synthesis technology platform to provide sustainable and affordable peptides for human health and beauty, and to provide key intermediates of semaglutide and tirzepatide and the oral enhancer SNAC to the industry.